v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 25,841 $ 92,942
Short-term investments 25,884 149,877
Restricted cash 146 146
Accounts receivable 34,108 40,221
Inventories 9,706 1,586
Other current assets 6,184 10,308
Total current assets 101,869 295,080
Property and equipment, net 3,856 6,300
Operating lease assets 54,935 68,022
Other assets 4,844 7,018
Total assets 165,504 376,420
Current liabilities:    
Accounts payable 3,684 6,871
Accrued compensation 11,519 17,659
Accrued research and development expenses 17,364 24,992
Deferred revenue 77,833 8,000
Other current liabilities 31,826 21,394
Total current liabilities 142,226 78,916
Deferred revenue - long-term 37,562 77,000
Operating lease liabilities - long-term 45,693 58,064
Liability related to the sale of future revenues - long-term 34,623 30,236
Other long-term liabilities 4,631 5,564
Total liabilities 264,735 249,780
Commitments and contingencies (Note 10)
Stockholders' equity (deficit):    
Common stock-$0.0001 par value, 500,000 shares authorized as of December 31, 2023 and 2022, respectively; 106,447 and 95,927 shares issued and outstanding as of December 31, 2023 and 2022, respectively 11 10
Additional paid-in capital 1,870,112 1,821,721
Accumulated other comprehensive (loss) income (204) (2,067)
Accumulated deficit (1,969,150) (1,693,024)
Total stockholders' equity (deficit) (99,231) 126,640
Total liabilities and stockholders' equity (deficit) $ 165,504 $ 376,420

Source

10-K
HTML PDF
XBRL
ZIP